NasdaqGS:MDGLBiotechs
Is It Too Late To Consider Madrigal Pharmaceuticals After Its Huge 2025 Share Price Surge?
If you are wondering whether Madrigal Pharmaceuticals is still worth buying after its huge run, you are not alone. This is exactly the kind of setup where valuation really matters.
Despite a recent pullback, with the stock down 4.7% over the last week and 2.0% over the past month, it is still up 73.5% year to date and 76.5% over the last year. A massive 353.2% gain over five years hints at how quickly sentiment can shift.
Those swings have come as investors digest a stream of regulatory and...